Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)

dc.contributor.authorUgarte-Gil, M.F.es_ES
dc.contributor.authorWojdyla, D.es_ES
dc.contributor.authorPons-Estel, G.J.es_ES
dc.contributor.authorCatoggio L.J.es_ES
dc.contributor.authorDrenkard, C.es_ES
dc.contributor.authorSarano, J.es_ES
dc.contributor.authorBerbotto, G.A.es_ES
dc.contributor.authorBorba, E.F.es_ES
dc.contributor.authorSato, E.I.es_ES
dc.contributor.authorTavares Brenol, J.C.es_ES
dc.contributor.authorUribe, O.es_ES
dc.contributor.authorRamirez Gómez, L.A.es_ES
dc.contributor.authorGuibert-Toledano, M.es_ES
dc.contributor.authorMassardo, L.es_ES
dc.contributor.authorCardiel, M.H.es_ES
dc.contributor.authorSilveira, L.H.es_ES
dc.contributor.authorChacón-Diaz, R.es_ES
dc.contributor.authorAlarcón, G.S.es_ES
dc.contributor.authorPons-Estel, B.A.es_ES
dc.contributor.authorGLADELes_ES
dc.date.accessioned6/22/2022 13:33
dc.date.accessioned2022-09-30T16:54:28Z
dc.date.available6/22/2022 13:33
dc.date.available2022-09-30T16:54:28Z
dc.date.issued2017
dc.description.abstractOBJECTIVE: To evaluate disease activity statuses' (DAS') impact on systemic lupus erythematosus (SLE) outcomes.MATERIALS AND METHODS: Four DAS were defined: remission off-therapy: SLE Disease Activity Index (SLEDAI)=0, no prednisone or immunosuppressive drugs (IS); remission on-therapy: SLEDAI=0, prednisone ≤5 mg/day and/or IS (maintenance); low (L) DAS: SLEDAI ≤4, prednisone ≤7.5 mg/day and/or IS (maintenance); non-optimally controlled: SLEDAI >4 and/or prednisone >7.5 mg/day and/or IS (induction). Antimalarials were allowed in all. Predefined outcomes were mortality, new damage (increase of at least one Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI) point) and severe new damage (increase of at least 3 SDI points). Univariable and multivariable Cox regression models were performed to define the impact of DAS, as time-dependent variable, on these outcomes.RESULTS: 1350 patients were included, 79 died during follow-up, 606 presented new and 177 severe new damage. In multivariable analyses, remission (on/off-therapy) was associated with a lower risk of new (HR 0.60; 95% CI 0.43 to 0.85), and of severe new damage (HR 0.32; 95% CI 0.15 to 0.68); low disease activity status (LDAS) was associated with a lower risk of new damage (HR 0.66; 95% CI 0.48 to 0.93) compared with non-optimally controlled. No significant effect on mortality was observed.CONCLUSIONS: Remission was associated with a lower risk of new and severe new damage; LDAS with a lower risk of new damage after adjusting for other damage confounders. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.es_ES
dc.formatapplication/pdfes_ES
dc.identifier.doi10.1136/annrheumdis-2017-211814es_ES
dc.identifier.urihttps://doi.org/10.1136/annrheumdis-2017-211814
dc.language.isoenges_ES
dc.rightsinfo:eu-repo/semantics/closedAccesses_ES
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/es_ES
dc.sourceAnnals of the rheumatic diseaseses_ES
dc.subjectBiochemistry, Genetics and Molecular Biologyes_ES
dc.subjectImmunology and Microbiologyes_ES
dc.subjectMedicinees_ES
dc.subject.ocdehttp://purl.org/pe-repo/ocde/ford#1.06.03es_ES
dc.titleRemission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersiones_ES
Archivos
Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
305. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence data from a multiethnic, multinational....PDF
Tamaño:
295.42 KB
Formato:
Adobe Portable Document Format
Colecciones